Related Experiment Video
Updated: Jun 16, 2026

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
Published on: May 25, 2020
Comparison of Clarus, Optos, and Heidelberg Systems for Geographic Atrophy Area Measurements
Jacob Bogost1,2, Thomas Saunders2, Jennifer Heathcote2
1A-EYE Research Unit, Dept of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin.
Purpose:
To compare geographic atrophy (GA) area measurements across 3 modern fundus autofluorescence (FAF) imaging platforms: Heidelberg Spectralis, Optos California, and Zeiss Clarus 700.
Design:
A prospective, single-center, cross-sectional comparative imaging study.
Participants:
Sixty-one eyes from 39 participants aged ≥50 years with GA secondary to age-related macular degeneration.
Methods:
Participants were imaged sequentially on the same day with all 3 devices: Optos California FAF (532 nm green excitation, 200° ultra-widefield), Zeiss Clarus 700 FAF (blue 435-500 nm and green 500-585 nm channels, 133° widefield), and Heidelberg Spectralis FAF (488 nm blue excitation, 30° field). Geographic atrophy was segmented with manual planimetry for all modalities; Heidelberg images were also segmented semiautomatically with RegionFinder. RegionFinder area values served as the reference standard for comparisons.
Main Outcome Measures:
Mean GA area by imaging system and agreement with RegionFinder.
Results:
Agreement with RegionFinder was high across imaging systems (intraclass correlation coefficients: 0.96-0.99), but systematic differences were noted in GA area measurements. Geographic atrophy measured larger on average with Clarus Green and Heidelberg manual planimetry (0.49 mm2 [95% confidence interval [CI], 0.23 to 0.75] and 0.34 mm2 [95% CI, 0.22 to 0.45], respectively), while Optos California measured smaller areas (-0.47 mm2 [95% CI, -0.81 to -0.13]).
Conclusions:
Geographic atrophy area measurements are reproducible within each FAF imaging system but systematically differ between platforms and wavelengths. Repeated use with the same device recommended for clinical trials.
Financial Disclosures:
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
